Mechanisms of trastuzumab resistance in breast cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 348-355

  Tolaney, Sara M ^a   Krop, Ian E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; CANERTINIB; CAPECITABINE; CARNETINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; KOS 1022; LAPATINIB; PERIFOSINE; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRO 132365; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CHILL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG BINDING; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; HUMAN; HYPERSENSITIVITY REACTION; NAUSEA; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 65549170412     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909030348     Document Type: Review

References (86)

1. Gschwind, A.; Fischer, O. M.; Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 2004, 4(5), 361-70.
2. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785), 177-82.
3. Lin, N. U.; Bellon, J. R.; Winer, E. P. CNS metastases in breast cancer. J. Clin. Oncol. 2004, 22(17), 3608-17.
4. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344(11), 783-92.
5. Romond, E. H.; Perez, E. A.; Bryant, J.; Suman, V. J.; Geyer, C. E., Jr.; Davidson, N. E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P. A.; Swain, S. M.; Pisansky, T. M.; Fehrenbacher, L.; Kutteh, L. A.; Vogel, V. G.; Visscher, D. W.; Yothers, G.; Jenkins, R. B.; Brown, A. M.; Dakhil, S. R.; Mamounas, E. P.; Lingle, W. L.; Klein, P. M.; Ingle, J. N.; Wolmark, N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353(16), 1673-84.
6. Vogel, C. L.; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M.; Shak, S.; Stewart, S. J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20(3), 719-26.
7. Cobleigh, M. A.; Vogel, C. L.; Tripathy, D.; Robert, N. J.; Scholl, S.; Fehrenbacher, L.; Wolter, J. M.; Paton, V.; Shak, S.; Lieberman, G.; Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17(9), 2639-48.
8. Lan, K. H.; Lu, C. H.; Yu, D. Mechanisms of trastuzumab resistance and their clinical implications. Ann. NY Acad. Sci. 2005, 1059, 70-5.
9. Esteva, F. J.; Valero, V.; Booser, D.; Guerra, L. T.; Murray, J. L.; Pusztai, L.; Cristofanilli, M.; Arun, B.; Esmaeli, B.; Fritsche, H. A.; Sneige, N.; Smith, T. L.; Hortobagyi, G. N. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20(7), 1800-8.
10. Seidman, A. D.; Fornier, M. N.; Esteva, F. J.; Tan, L.; Kaptain, S.; Bach, A.; Panageas, K. S.; Arroyo, C.; Valero, V.; Currie, V.; Gilewski, T.; Theodoulou, M.; Moynahan, M. E.; Moasser, M.; Sklarin, N.; Dickler, M.; D'Andrea, G.; Cristofanilli, M.; Rivera, E.; Hortobagyi, G. N.; Norton, L.; Hudis, C. A. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 2001, 19(10), 2587-95.
11. Slamon D, E. W., Robert N, Pienkowski T, Martin M, Pawlicki M, Chan M, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J on behalf of the BCIRG 006 Investigators Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium; Dec. 8-11, 2005; San Antonio, Texas, 2005, Abstract 1.
12. Nahta, R.; Esteva, F. J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8(6), 215.
13. Yakes, F. M.; Chinratanalab, W.; Ritter, C. A.; King, W.; Seelig, S.; Arteaga, C. L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62(14), 4132-41.
14. Lane, H. A.; Motoyama, A. B.; Beuvink, I.; Hynes, N. E. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann. Oncol. 2001, 12(Suppl 1), S21-2.
15. Cuello, M.; Ettenberg, S. A.; Clark, A. S.; Keane, M. M.; Posner, R. H.; Nau, M. M.; Dennis, P. A.; Lipkowitz, S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61(12), 4892-900.
16. Gennari, R.; Menard, S.; Fagnoni, F.; Ponchio, L.; Scelsi, M.; Tagliabue, E.; Castiglioni, F.; Villani, L.; Magalotti, C.; Gibelli, N.; Oliviero, B.; Ballardini, B.; Da Prada, G.; Zambelli, A.; Costa, A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 2004, 10(17), 5650-5.
17. Burstein, H. J.; Harris, L. N.; Gelman, R.; Lester, S. C.; Nunes, R. A.; Kaelin, C. M.; Parker, L. M.; Ellisen, L. W.; Kuter, I.; Gadd, M. A.; Christian, R. L.; Kennedy, P. R.; Borges, V. F.; Bunnell, C. A.; Younger, J.; Smith, B. L.; Winer, E. P. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol. 2003, 21(1), 46-53.
18. Longva, K. E.; Pedersen, N. M.; Haslekas, C.; Stang, E.; Madshus, I. H. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer 2005, 116(3), 359-67.
19. Austin, C. D.; De Maziere, A. M.; Pisacane, P. I.; van Dijk, S. M.; Eigenbrot, C.; Sliwkowski, M. X.; Klumperman, J.; Scheller, R. H. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 2004, 15(12), 5268-82.
20. Clynes, R. A.; Towers, T. L.; Presta, L. G.; Ravetch, J. V. Inhibitory Fc receptors modulate in. vivo cytoxicity against tumor targets. Nat. Med. 2000, 6(4), 443-6.
21. Valabrega, G.; Montemurro, F.; Aglietta, M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007, 18(6), 977-84.
22. Cooley, S.; Burns, L. J.; Repka, T.; Miller, J. S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp. Hematol. 1999, 27(10), 1533-41.
23. Repka, T.; Chiorean, E. G.; Gay, J.; Herwig, K. E.; Kohl, V. K.; Yee, D.; Miller, J. S. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin. Cancer Res. 2003, 9(7), 2440-6.
24. Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Bisagni, G.; Neri, T. M.; Ardizzoni, A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26(11), 1789-96.
25. Gianni, L. The "other" signaling of trastuzumab: antibodies are immunocompetent drugs. J. Clin. Oncol. 2008, 26(11), 1778-80.
26. Izumi, Y.; Xu, L.; di Tomaso, E.; Fukumura, D.; Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416(6878), 279-80.
27. Molina, M. A.; Codony-Servat, J.; Albanell, J.; Rojo, F.; Arribas, J.; Baselga, J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61(12), 4744-9.
28. Hancock, M. C.; Langton, B. C.; Chan, T.; Toy, P.; Monahan, J. J.; Mischak, R. P.; Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichlo roplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991, 51(17), 4575-80.
29. Pietras, R. J.; Fendly, B. M.; Chazin, V. R.; Pegram, M. D.; Howell, S. B.; Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9(7), 1829-38.
30. Pietras, R. J.; Poen, J. C.; Gallardo, D.; Wongvipat, P. N.; Lee, H. J.; Slamon, D. J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999, 59(6), 1347-55.
31. Walsh, M. D.; McGuckin, M. A.; Devine, P. L.; Hohn, B. G.; Wright, R. G. Expression of MUC2 epithelial mucin in breast carcinoma. J. Clin. Pathol. 1993, 46(10), 922-5.
32. Carraway, K. L.; Price-Schiavi, S. A.; Komatsu, M.; Jepson, S.; Perez, A.; Carraway, C. A. Muc4/sialomucin complex in the mammary gland and breast cancer. J. Mammary Gland. Biol. Neoplasia 2001, 6(3), 323-37.
33. Carraway, K. L., 3rd; Rossi, E. A.; Komatsu, M.; Price-Schiavi, S. A.; Huang, D.; Guy, P. M.; Carvajal, M. E.; Fregien, N.; Carraway, C. A.; Carraway, K. L. An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J. Biol. Chem. 1999, 274(9), 5263-6.
34. Price-Schiavi, S. A.; Jepson, S.; Li, P.; Arango, M.; Rudland, P. S.; Yee, L.; Carraway, K. L. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 2002, 99(6), 783-91.
35. Nagy, P.; Friedlander, E.; Tanner, M.; Kapanen, A. I.; Carraway, K. L.; Isola, J.; Jovin, T. M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005, 65(2), 473-82.
36. Stephens, P.; Hunter, C.; Bignell, G.; Edkins, S.; Davies, H.; Teague, J.; Stevens, C.; O'Meara, S.; Smith, R.; Parker, A.; Barthorpe, A.; Blow, M.; Brackenbury, L.; Butler, A.; Clarke, O.; Cole, J.; Dicks, E.; Dike, A.; Drozd, A.; Edwards, K.; Forbes, S.; Foster, R.; Gray, K.; Greenman, C.; Halliday, K.; Hills, K.; Kosmidou, V.; Lugg, R.; Menzies, A.; Perry, J.; Petty, R.; Raine, K.; Ratford, L.; Shepherd, R.; Small, A.; Stephens, Y.; Tofts, C.; Varian, J.; West, S.; Widaa, S.; Yates, A.; Brasseur, F.; Cooper, C. S.; Flanagan, A. M.; Knowles, M.; Leung, S. Y.; Louis, D. N.; Looijenga, L. H.; Malkowicz, B.; Pierotti, M. A.; Teh, B.; Chenevix-Trench, G.; Weber, B. L.; Yuen, S. T.; Harris, G.; Goldstraw, P.; Nicholson, A. G.; Futreal, P. A.; Wooster, R.; Stratton, M. R., Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431, (7008), 525-6.
37. Lee, J. W.; Soung, Y. H.; Seo, S. H.; Kim, S. Y.; Park, C. H.; Wang, Y. P.; Park, K.; Nam, S. W.; Park, W. S.; Kim, S. H.; Lee, J. Y.; Yoo, N. J.; Lee, S. H. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin. Cancer Res. 2006, 12(1), 57-61.
38. Khoury T, M. W., Hicks DG, Janarthanan B, Tan J, Tian C, Cheney RT. Trastuzumab binding site mutations in HER2 positive invasive breast cancer: a potential predictor of less aggressive disease and trastuzumab resistance. San Antonio Breast Conference, December 14-17, 2006, Abstract #308.
39. Ji, H.; Zhao, X.; Yuza, Y.; Shimamura, T.; Li, D.; Protopopov, A.; Jung, B. L.; McNamara, K.; Xia, H.; Glatt, K. A.; Thomas, R. K.; Sasaki, H.; Horner, J. W.; Eck, M.; Mitchell, A.; Sun, Y.; Al-Hashem, R.; Bronson, R. T.; Rabindran, S. K.; Discafani, C. M.; Maher, E.; Shapiro, G. I.; Meyerson, M.; Wong, K. K. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA 2006, 103(20), 7817-22.
40. Azuma, M.; Danenberg, K. D.; Iqbal, S.; El-Khoueiry, A.; Zhang, W.; Yang, D.; Koizumi, W.; Saigenji, K.; Danenberg, P. V.; Lenz, H. J. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin. Colorectal. Cancer 2006, 6(3), 214-8.
41. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1(9), 707-17.
42. Nagata, Y.; Lan, K. H.; Zhou, X.; Tan, M.; Esteva, F. J.; Sahin, A. A.; Klos, K. S.; Li, P.; Monia, B. P.; Nguyen, N. T.; Hortobagyi, G. N.; Hung, M. C.; Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2), 117-27.
43. Lu, Y.; Lin, Y. Z.; LaPushin, R.; Cuevas, B.; Fang, X.; Yu, S. X.; Davies, M. A.; Khan, H.; Furui, T.; Mao, M.; Zinner, R.; Hung, M. C.; Steck, P.; Siminovitch, K.; Mills, G. B. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 1999, 18(50), 7034-45.
44. Lee, J. W.; Soung, Y. H.; Kim, S. Y.; Lee, H. W.; Park, W. S.; Nam, S. W.; Kim, S. H.; Lee, J. Y.; Yoo, N. J.; Lee, S. H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005, 24(8), 1477-80.
45. Isakoff, S. J.; Engelman, J. A.; Irie, H. Y.; Luo, J.; Brachmann, S. M.; Pearline, R. V.; Cantley, L. C.; Brugge, J. S. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005, 65(23), 10992-1000.
46. Berns, K.; Horlings, H. M.; Hennessy, B. T.; Madiredjo, M.; Hijmans, E. M.; Beelen, K.; Linn, S. C.; Gonzalez-Angulo, A. M.; Stemke-Hale, K.; Hauptmann, M.; Beijersbergen, R. L.; Mills, G. B.; van de Vijver, M. J.; Bernards, R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4), 395-402.
47. Lu, Y.; Zi, X.; Pollak, M. Molecular mechanisms underlying IGFI-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 2004, 108(3), 334-41.
48. Nahta, R.; Yuan, L. X.; Zhang, B.; Kobayashi, R.; Esteva, F. J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65(23), 11118-28.
49. Motoyama, A. B.; Hynes, N. E.; Lane, H. A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002, 62(11), 3151-8.
50. Camp, R. L.; Rimm, E. B.; Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86(11), 2259-65.
51. Ghoussoub, R. A.; Dillon, D. A.; D'Aquila, T.; Rimm, E. B.; Fearon, E. R.; Rimm, D. L. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998, 82(8), 1513-20.
52. Lee, W. Y.; Chen, H. H.; Chow, N. H.; Su, W. C.; Lin, P. W.; Guo, H. R. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin. Cancer Res. 2005, 11(6), 2222-8.
53. Khoury, H.; Naujokas, M. A.; Zuo, D.; Sangwan, V.; Frigault, M. M.; Petkiewicz, S.; Dankort, D. L.; Muller, W. J.; Park, M. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol. Biol. Cell 2005, 16(2), 550-61.
54. Shattuck, D. L.; Miller, J. K.; Carraway, K. L., 3rd; Sweeney, C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008, 68(5), 1471-7.
55. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C. M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Janne, P. A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827), 1039-43.
56. Engelman, J. A.; Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2008, 14(10), 2895-9.
57. Nahta, R.; Hung, M. C.; Esteva, F. J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64(7), 2343-6.
58. Tanner, M.; Kapanen, A. I.; Junttila, T.; Raheem, O.; Grenman, S.; Elo, J.; Elenius, K.; Isola, J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol. Cancer Ther. 2004, 3(12), 1585-92.
59. Gelmon KA, F. P., Verma S, Wardley AM, Conte PF, Miles D, Gianni L, McNally VA, Ross G, Baselga J. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J. Clin. Oncol. 2008, 26(20 Suppl), abstract 1026.
60. von Minckwitz, G.; Harder, S.; Hovelmann, S.; Jager, E.; Al-Batran, S. E.; Loibl, S.; Atmaca, A.; Cimpoiasu, C.; Neumann, A.; Abera, A.; Knuth, A.; Kaufmann, M.; Jager, D.; Maurer, A. B.; Wels, W. S. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005, 7(5), R617-26.
61. Beeram M, B. H., Modi S, Birkner M, Girish S, Tibbitts J, Holden SN, Lutzker SG, Krop IE. A phase I study of trastuzumab-DM1 (TDM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). J. Clin. Oncol. 2008, 26(Suppl), abstract 1028.
62. Holden SN, B. M., Krop IE, Burris A, Birkner M, Girish S, Tibbitts J, Lutzker SG, Modi S. A phase I study of weekly dosing of trastuzumab-DM1 in patients with advanced HER2+ breast cancer. J. Clin. Oncol. 2008, 26(Suppl), abstract 1029.
63. Konecny, G. E.; Pegram, M. D.; Venkatesan, N.; Finn, R.; Yang, G.; Rahmeh, M.; Untch, M.; Rusnak, D. W.; Spehar, G.; Mullin, R. J.; Keith, B. R.; Gilmer, T. M.; Berger, M.; Podratz, K. C.; Slamon, D. J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006, 66(3), 1630-9.
64. Blackwell KL, K. E., Franco SX, Marcom PK, Maleski JE, Sorensen MJ, Berger MS. In A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 22(14S), ASCO Annual Meeting Proceedings, Abstract 3006, July 15(Suppl), 2004; ASCO Annual Meeting Proceedings, 2004, Abstract 3006.
65. Geyer, C. E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C. G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S. D.; Stein, S.; Cameron, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355(26), 2733-43.
66. Lin, N., Dieras V, Paul D, Lossignol D, Christodoulou C, Laessig D, Roche H, Zembryki D, Oliva CR, Winer EP. EGF105084, a phase II study of lapatinib for brain metastases in patients with HER2+ breast cancer following trastuzumab based systemic therapy and cranial radiotherapy (RT). J. Clin. Oncol. 2007, 25(18S), Abstract 1012.
67. Slichenmyer, W. J.; Elliott, W. L.; Fry, D. W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol. 2001, 28(5 Suppl 16), 80-5.
68. Nemunaitis, J.; Eiseman, I.; Cunningham, C.; Senzer, N.; Williams, A.; Lenehan, P. F.; Olson, S. C.; Bycott, P.; Schlicht, M.; Zentgraff, R.; Shin, D. M.; Zinner, R. G. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin. Cancer Res. 2005, 11(10), 3846-53.
69. Wong KK, F. P., Bukowski RM, Munster PN, Lynch T, Abbas R, Quinn SE, Zacharchuk C, Burris H. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase I results in patients with solid tumors. J. Clin. Oncol. 2006, 24(18S), 3018.
70. Burstein, H., Awada A, Badwe R, Dirix L, Tan A, Jacod S, Lustgarten S, Vermette J, Zacharachuk C. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer. San Antonio Breast Conference, December 14-17, 2007, Abstract #6061.
71. Mom CH, E. F., Gietema JA, Nooter K, De Jonge MJ, Amelsberg A, Huisman H, Stopfer P, De Vries EG, Verweij J. Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule. J. Clin. Oncol. 2006, 24(18S), 3025.
72. Erlichman, C.; Hidalgo, M.; Boni, J. P.; Martins, P.; Quinn, S. E.; Zacharchuk, C.; Amorusi, P.; Adjei, A. A.; Rowinsky, E. K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 2006, 24(15), 2252-60.
73. Li, X.; Luwor, R.; Lu, Y.; Liang, K.; Fan, Z. Enhancement of anti-tumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 2006, 25(4), 525-35.
74. Crul, M.; Rosing, H.; de Klerk, G. J.; Dubbelman, R.; Traiser, M.; Reichert, S.; Knebel, N. G.; Schellens, J. H.; Beijnen, J. H.; ten Bokkel Huinink, W. W. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer 2002, 38(12), 1615-21.
75. Van Ummersen, L.; Binger, K.; Volkman, J.; Marnocha, R.; Tutsch, K.; Kolesar, J.; Arzoomanian, R.; Alberti, D.; Wilding, G. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin. Cancer Res. 2004, 10(22), 7450-6.
76. Hidalgo, M.; Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19(56), 6680-6.
77. Chan, S.; Scheulen, M. E.; Johnston, S.; Mross, K.; Cardoso, F.; Dittrich, C.; Eiermann, W.; Hess, D.; Morant, R.; Semiglazov, V.; Borner, M.; Salzberg, M.; Ostapenko, V.; Illiger, H. J.; Behringer, D.; Bardy-Bouxin, N.; Boni, J.; Kong, S.; Cincotta, M.; Moore, L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 2005, 23(23), 5314-22.
78. Beliakoff, J.; Whitesell, L. Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 2004, 15(7), 651-62.
79. Modi S, S. A., Linden H, et al. Phase 2 Trial of Trastuzumab and KOS-953 (Tanespimycin) in patients with HER2-positive breast cancer: preliminary results. The 29th Annual San Antonio Breast Conference, Dec. 14-17, 2006. 2006, Abstract 1102.
80. Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; Cropp, G. F.; Johnson, R. G.; Hannah, A. L.; Hudis, C. A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 2007, 25(34), 5410-7.
81. Modi S, S. A., Kinden H, Sugarman S, Ma W, Solit D, Kersey K, Johnson R, Hannah AL, Hudis C., Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial. San Antonio Breast Conference, December 14-17, 2007, Abstract #6066.
82. Fuino, L.; Bali, P.; Wittmann, S.; Donapaty, S.; Guo, F.; Yamaguchi, H.; Wang, H. G.; Atadja, P.; Bhalla, K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2003, 2(10), 971-84.
83. Knutson, K. L.; Schiffman, K.; Cheever, M. A.; Disis, M. L. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 2002, 8(5), 1014-8.
84. Bernhard, H.; Salazar, L.; Schiffman, K.; Smorlesi, A.; Schmidt, B.; Knutson, K. L.; Disis, M. L. Vaccination against the HER-2/neu oncogenic protein. Endocr. Relat. Cancer 2002, 9(1), 33-44.
85. Disis, M. L.; Gooley, T. A.; Rinn, K.; Davis, D.; Piepkorn, M.; Cheever, M. A.; Knutson, K. L.; Schiffman, K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 2002, 20(11), 2624-32.
86. Yu, D.; Suen, T. C.; Yan, D. H.; Chang, L. S.; Hung, M. C. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc. Natl. Acad. Sci. USA 1990, 87(12), 4499-503.